WO2010067986A2 - Composition for controlling gastrointestinal tract movement - Google Patents
Composition for controlling gastrointestinal tract movement Download PDFInfo
- Publication number
- WO2010067986A2 WO2010067986A2 PCT/KR2009/007215 KR2009007215W WO2010067986A2 WO 2010067986 A2 WO2010067986 A2 WO 2010067986A2 KR 2009007215 W KR2009007215 W KR 2009007215W WO 2010067986 A2 WO2010067986 A2 WO 2010067986A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composite composition
- intestinal motility
- motility disorder
- controlling
- movement
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Abstract
The present invention provides a novel composite composition for controlling gastrointestinal tract movement comprising an enkephaline receptor agonist and a prokinetic agent. The composite composition provided according to the present invention is a general purpose composite composition for controlling movement of the upper and lower gastrointestinal tracts that enables improved movement controlling capabilities of the upper and lower gastrointestinal tracts in a complementary fashion, based on mutually different mechanisms of an enkephaline receptor agonist and a prokinetic agent. Thus, this is a novel composite composition that exhibits inclusive and effective therapeutic actions on various diseases including functional gastrointestinal disturbance, constipation, and irritable bowel syndrome as well as diabetic intestinal motility disorder, intestinal motility disorder caused by chemotherapy, ileus caused by intestinal motility disorder, and intestinal motility disorder in myotonic dystrophy patients.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2008-0124068 | 2008-12-08 | ||
KR1020080124068A KR100991032B1 (en) | 2008-12-08 | 2008-12-08 | Novel Pharmaceutical Composition For Effective Control Of GI Motility |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010067986A2 true WO2010067986A2 (en) | 2010-06-17 |
WO2010067986A3 WO2010067986A3 (en) | 2010-09-10 |
Family
ID=42243174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/007215 WO2010067986A2 (en) | 2008-12-08 | 2009-12-04 | Composition for controlling gastrointestinal tract movement |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100991032B1 (en) |
WO (1) | WO2010067986A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101154043B1 (en) | 2011-07-01 | 2012-06-07 | 주식회사 에코덤 | Pharmaceutical composition and food composition for preventing or improving gastro-intestinal motility disorder |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6548501B2 (en) * | 2000-05-31 | 2003-04-15 | Pfizer Inc. | Composition and methods for stimulating gastrointestinal motility |
US6986901B2 (en) * | 2002-07-15 | 2006-01-17 | Warner-Lambert Company Llc | Gastrointestinal compositions |
-
2008
- 2008-12-08 KR KR1020080124068A patent/KR100991032B1/en active IP Right Grant
-
2009
- 2009-12-04 WO PCT/KR2009/007215 patent/WO2010067986A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6548501B2 (en) * | 2000-05-31 | 2003-04-15 | Pfizer Inc. | Composition and methods for stimulating gastrointestinal motility |
US6986901B2 (en) * | 2002-07-15 | 2006-01-17 | Warner-Lambert Company Llc | Gastrointestinal compositions |
Non-Patent Citations (1)
Title |
---|
OK HWA JHEE ET AL.: 'Pharmacokinetic and bioequivalence evaluation of two or mulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers sing the LC-MS/MS method' CLIN. CHIM. ACTA. vol. 375, no. 1-2, January 2007, pages 69 - 75 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010067986A3 (en) | 2010-09-10 |
KR20100065643A (en) | 2010-06-17 |
KR100991032B1 (en) | 2010-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010027567A3 (en) | Tricyclic spirocycle derivatives and methods of use thereof | |
CL2007003261A1 (en) | COMPOUNDS DERIVED FROM 1,4-BENZOTIEPINA-1,1-DIOXIDE; PHARMACEUTICAL COMPOSITION; AND ITS USE FOR THE TREATMENT OF LIPID METABOLISM DISORDERS, HYPERLIPIDEMIA, INSULIN RESISTANCE, DIABETES AND CNS DISORDERS, SUCH AS SCHIZOPHRENIA, | |
WO2008097428A3 (en) | Compounds and compositions as modulators of gpr119 activity | |
WO2010123930A3 (en) | Chemosensory receptor ligand-based therapies | |
WO2007067616A3 (en) | Uses of myostatin antagonists | |
CL2008001125A1 (en) | COMPOUNDS DERIVED FROM PIRIMIDINONE CONDENSED WITH HETEROCICLES; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DIABETES, METABOLIC SYNDROME AND OBESITY. | |
EA201891432A1 (en) | SUBSTITUTED 4-PHENYLPYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | |
MX2015001500A (en) | Antidiabetic tricyclic compounds. | |
CL2008001126A1 (en) | COMPOUNDS DERIVED FROM PIRIMIDINONE CONDENSED WITH HETEROCICLES; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DIABETES, METABOLIC SYNDROME AND OBESITY. | |
WO2007104789A3 (en) | Amylin derivatives | |
DE602007004324D1 (en) | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer | |
CY1112398T1 (en) | CYROLOXYL PYROLYLIDINE SUBSTITUTES AS 11-B-HYDROXYSTEROHYDROHYDROHOUSE INHIBITIONS 1 | |
WO2012054526A8 (en) | Chemosensory receptor ligand-based therapies | |
DE602007007473D1 (en) | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer | |
WO2013158928A3 (en) | Chemosensory receptor ligand-based therapies | |
WO2007148208A3 (en) | Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands | |
EA201170198A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DOPAMINE RECEPTOR LIGANDS | |
CL2007003629A1 (en) | ARIL-SUBSTITUTED HETEROCICLIC COMPOUNDS, TYPE I CANNABINOID RECEIVER MODULATORS (CB1); PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS METABOLIC DISORDERS AND COGNITIVE DISORDERS. | |
CL2010001496A1 (en) | Compounds derived from (pyridin- or pyrimidin-) piperidine, gpr119 agonists; pharmaceutical composition; and its use for the treatment of type I diabetes, type II diabetes and related diseases such as metabolic syndrome, dyslipidemia and insulin resistance. | |
WO2010127856A8 (en) | Substituted phenylureas and phenylamides as vanilloid receptor ligands | |
SV2009003275A (en) | DERIVATIVES OF AZACICLOALCANS AS INHIBITORS FROM ESTEAROIL-COENZIMA TO DELTA-9 DESATURASA | |
EP2560660A4 (en) | Chemosensory receptor ligand-based therapies | |
WO2008019147A3 (en) | Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen | |
EA201100910A1 (en) | TREATMENT OF INFLAMMATORY DISEASES OF THE INTESTINE BETA-DEFENSINS OF MAMMALS | |
WO2010045303A3 (en) | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09832071 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09832071 Country of ref document: EP Kind code of ref document: A2 |